Modality
Multispecific
MOA
CAR-T CD19
Target
PRMT5
Pathway
STING
Ewing SarcomaHuntington's
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
→ Jul 2031
Phase 2Current
NCT05568991
1,948 pts·Ewing Sarcoma
2020-10→2031-07·Recruiting
1,948 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-165.3y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2031-07-16 · 5.3y away
Ewing Sarcoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05568991 | Phase 2/3 | Ewing Sarcoma | Recruiting | 1948 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |